Lacticaseibacillus rhamnosus HN001
Lacticaseibacillus rhamnosus HN001 (formerly classified as Lactobacillus rhamnosus HN001) has been studied across in vitro, animal, and human randomized controlled trial settings. In vitro research has examined activity against certain bacterial and fungal pathogens under laboratory conditions, while RCT-level evidence has examined constipation, IBS symptoms, and pregnancy-related outcomes. Animal model work has examined immune modulation and gut barrier function, though findings in animal models do not always translate directly to human outcomes. The available evidence is early to moderate in maturity; individual results may vary and this strain should not be viewed as a treatment for any specific condition. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 157 body-system-tagged papers that concern each system. Research coverage, not measured effect.
Symptoms in the research A tag means the paper's text names the symptom or condition — research coverage, not evidence of benefit. How we classify this →
Share of this strain's 84 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.
+15 more symptoms
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
213 papers reference this strain in the probiotic database.
Discussion
Be the first to comment.
Sign in to join the discussion.
Citations
Selected papers that name this strain.
-
[1]
Source →Lacticaseibacillus rhamnosus HN001 enhances intestinal barrier function and protects the blood-brain barrier from inflammatory disruption in vitro· AgResearch · 2026
-
[2]
PMID 42521749 →Probiotic effects on brain health are both transient and sustained for several weeks after discontinuation: a randomised controlled trial· Communications Medicine · 2026
-
[3]
PMID 42180834 →Lacticaseibacillus rhamnosus HN001 enhances intestinal barrier function and protects the blood-brain barrier from inflammatory disruption in vitro· Frontiers in Physiology · 2026
-
[4]
Source →Dataset for Lacticaseibacillus rhamnosus HN001 enhances intestinal barrier function and protects the blood-brain barrier from inflammatory disruption in vitro· AgResearch · 2026
-
[5]
PMID 35634695 →Adjuvant use of multispecies probiotic in the treatment of peri‐implant mucositis: A randomized controlled trial· Journal Of Clinical Periodontology · 2022
-
[6]
Source →Effects of Lactobacillus rhamnosus HN001 in Early Life on the Cumulative Prevalence of Allergic Disease to 11 Years· PEDIATRICS · 2019
-
[7]
PMID 30430649 →Effects of Lactobacillus rhamnosus HN001 in early life on the cumulative prevalence of allergic disease to 11 years· Pediatric Allergy and Immunology · 2018
-
[8]
PMID 29540160 →Effect of Lactobacillus rhamnosus HN001 on carriage of Staphylococcus aureus: results of the impact of probiotics for reducing infections in veterans (IMPROVE) study· BMC Infectious Diseases · 2018
-
[9]
PMID 28943228 →Effect of Lactobacillus rhamnosus HN001 in Pregnancy on Postpartum Symptoms of Depression and Anxiety: A Randomised Double-blind Placebo-controlled Trial· EBioMedicine · 2017
-
[10]
PMID 28367765 →Early pregnancy probiotic supplementation with Lactobacillus rhamnosus HN001 may reduce the prevalence of gestational diabetes mellitus: a randomised controlled trial· British Journal Of Nutrition · 2017